albumin binding is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Peptide degradation follows several routes. Hydrolysis cleaves the backbone at susceptible residues, oxidation targets methionine and tryptophan side chains, and aggregation produces higher-molecular-weight species that are difficult to reverse. Light exposure accelerates oxidation, which is why amber glass or opaque secondary packaging is common. Repeated freeze-thaw cycles promote aggregation and are best avoided. Stability-indicating methods detect these changes before they become visible.
Quality control for research material typically involves reversed-phase HPLC for purity and identity, mass spectrometry for molecular weight confirmation, and Karl Fischer titration for residual water content. Peptide content is often reported as the mass of actual peptide rather than total powder mass, since counterions and water contribute to the latter. A certificate of analysis should list the method used for each specification. Limits and acceptance criteria vary by supplier and by intended application.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Parent peptide; salt forms also reported |
| Molecular mass | about 4113.6 Da | Average mass of the free peptide |
| Peptide length | 31 amino acids | Backbone related to GLP-1(7-37) |
| Key substitution | Aib at position 8 | Blocks DPP-4 cleavage |
| Albumin binding | Via C-18 diacid side chain | Prolongs circulation time |
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
容器与密封系统同样参与稳定性表现。硅油涂层、胶塞材质与顶空氧含量可能改变聚集速率与氧化水平。分析结果因此需要在完整包装形式下评估，而不能仅凭原料药数据推断。法规文件通常要求同时提交批次数据与代表性容器中的稳定性趋势。
关于降解产物的免疫原性风险，文献中仍有讨论空间。体外聚集水平与临床免疫反应之间的定量关系尚未确立。多数公开研究只报告理化指标，缺少长期随访的对应数据。这一问题在生物类似物比对中尤其受到关注。
市售注射用制剂通常要求在二至八摄氏度冷藏保存，并避免光照与冻结。部分多剂量笔在首次使用后允许在不超过三十摄氏度的环境中存放有限周数，具体期限由辅料与防腐剂体系决定。反复冻融会促进肽链聚集并改变可见颗粒计数，因此应予避免。冻干粉末在干燥、避光、低温条件下更为稳定。溶液配制后宜使用低吸附容器，以减少肽类在塑料或玻璃表面的损失。
July 12: Law concerning freedom of higher education (for boys). July 24: "Women of ill repute" are kept away from the gendarmerie. 1879 August 9: Law establishing primary teacher training colleges: each department is required to have one, with a version for training male teachers and another for training female teachers—destined for communal schools. December 5: Decree organizing the General Inspectorate of Administrative Services of the Ministry of the Interior; among the planned measures is the creation of a post for a female general inspector—her salary is lower than that of her male counterparts; this general inspector is particularly in charge of inspecting girls' penal institutions and women's establishments. 1880
=== Science and technology === The National Science and Technology Council (CCT) and the National Fund for Scientific and Technological Development were also restructured, with the Minister of Science, Technology and Innovation Luciana Santos saying that the government would increase investments in that area. On 16 February, Lula announced yet another readjustment in the value of scholarships during an event in the Planalto Palace. and stated that "in this government it is forbidden to treat money that goes to education, scholarships, or healthcare as an expense." He later restructured the National Council for Science and Technology (CCT) and restored the National Fund for Scientific and Technological Development (FNDCT). The minister of science, technology and innovation, Luciana Santos, stated that investment in the area is a priority for the government.
The rear corridor, forming a back-room behind the central pillar, is a barrel-vaulted rectangular room with the two corridors for side access. It was decorated by many spectacular murals, including a large mural showing the sharing of the relics, with soldiers in armour riding horses and elephants (β on the plan). The vault was lavishly decorated with flying asparas holding musical instruments. The back wall had a depiction of the Parinirvana with a reclining image of the Buddha, and asparas flying over. The murals were photographed in black and white in-situ by Charles Nouette in September 1907, but all of them were later taken to Germany by Von Le Coq. A reconstruction of the rear corridor was recently built in the Museum für Asiatische Kunst.
If administered in the form of a radiocolloid it tends to concentrate in the liver. Experiments in rats and monkeys suggest that astatine-211 causes much greater damage to the thyroid gland than does iodine-131, with repetitive injection of the nuclide resulting in necrosis and cell dysplasia within the gland. Early research suggested that injection of astatine into female rodents caused morphological changes in breast tissue; this conclusion remained controversial for many years. General agreement was later reached that this was likely caused by the effect of breast tissue irradiation combined with hormonal changes due to irradiation of the ovaries. Trace amounts of astatine can be handled safely in fume hoods if they are well-aerated; biological uptake of the element must be avoided.
Sources: en.wikipedia.org
=== Signs and symptoms === The classic clinical syndrome for vitamin B6 deficiency is a seborrheic dermatitis-like eruption, atrophic glossitis with ulceration, angular cheilitis, conjunctivitis, intertrigo, abnormal electroencephalograms, microcytic anemia (due to impaired heme synthesis), and neurological symptoms of somnolence, confusion, depression, and neuropathy (due to impaired sphingosine synthesis). In infants, a deficiency in vitamin B6 can lead to irritability, abnormally acute hearing, and convulsive seizures. Less severe cases present with metabolic disease associated with insufficient activity of the coenzyme pyridoxal 5' phosphate (PLP). The most prominent of the lesions is due to impaired tryptophan–niacin conversion. This can be detected based on urinary excretion of xanthurenic acid after an oral tryptophan load. Vitamin B6 deficiency can also result in impaired transsulfuration of methionine to cysteine. The PLP-dependent transaminases and glycogen phosphorylase provide the vitamin with its role in gluconeogenesis, so deprivation of vitamin B6 results in impaired glucose tolerance.
A polyhistidine-tag, best known by the trademarked name His-tag, is an amino acid motif in proteins that typically consists of at least six histidine (His) residues, often at the N- or C-terminus of the protein. It is also known as a hexa histidine-tag, 6xHis-tag, or His6 tag. The tag was invented by Roche, although the use of histidines and its vectors are distributed by Qiagen. Various purification kits for histidine-tagged proteins are commercially available from multiple companies. The total number of histidine residues may vary in the tag from as low as two, to as high as 10 or more His residues. N- or C-terminal His-tags may also be followed or preceded, respectively, by a suitable amino acid sequence that facilitates removal of the polyhistidine-tag using endopeptidases. This extra sequence is not necessary if exopeptidases are used to remove N-terminal His-tags (e.g., Qiagen TAGZyme). Furthermore, exopeptidase cleavage may solve the unspecific cleavage observed when using endoprotease-based tag removal. Polyhistidine-tags are often used for affinity purification of genetically modified proteins.
Dy2O3 + 6 HClO4 → 2 Dy(ClO4)3 + 3 H2O Solutions used in modern spectroscopic work have been prepared directly from Dy2O3 and concentrated perchloric acid. Dysprosium perchlorate hexahydrate has also been obtained by dissolving Dy2O3 in 50–60% perchloric acid, followed by removal of excess water under reduced pressure or by freeze-drying. Anhydrous Dy(ClO4)3 can be obtained by controlled dehydration of hydrated dysprosium perchlorate.
Sources: en.wikipedia.org
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.
The side chain enables reversible binding to albumin in the bloodstream, which protects the peptide from rapid renal clearance. This extends the interval between administrations compared with unmodified GLP-1.
No. It shares much of the native sequence but carries substitutions and an added side chain. These changes increase stability against enzymatic breakdown.
Sealed, protected from light, and refrigerated at two to eight degrees Celsius for most research material. Desiccated storage limits moisture uptake. Allow the vial to reach room temperature before opening to prevent condensation.